BioCryst Pharmaceuticals is trading at $9.80 (+8.65%) following a strong Q2 2026 earnings report and an upward revision to its full-year guidance.
- The company reported revenue of $218.3 million and a diluted EPS of $0.30, both exceeding analyst expectations.
- Results were significantly bolstered by $55.7 million in upfront revenue from a European licensing agreement for navenibart.
- Management raised the FY26 outlook, further fueling investor optimism ahead of the market open.